A coalition of taxpayer and free-market advocacy groups is urging U.S. officials to address Japan’s pharmaceutical pricing policies during upcoming discussions with Japanese Prime Minister Sanae Takaichi.
In a March 18 letter to U.S. Trade Representative Jamieson Greer and Japanese Ambassador George Glass, the organizations said Japan’s government price controls on medicines place an unfair burden on American patients and undermine medical innovation.
“For far too long, wealthy nations such as Japan have benefited from American medical innovation while implementing costly price controls on medications that result in higher prices on U.S. consumers,” the coalition wrote in the letter.Â
“Japan relies heavily on government price-setting policies that artificially suppress the price of innovative medicines,” the letter continued. “As a result, Japan pays roughly half as much as Americans do for new treatments.”Â
The letter argues that these policies shift the cost of pharmaceutical research and development onto U.S. patients and taxpayers, reducing investment in innovation and job creation. The coalition also warned that the imbalance could weaken broader economic ties between the two countries if not addressed.
The groups called on the Trump administration to use ongoing trade negotiations to push for changes to Japan’s pricing system, stating that “wealthy allied nations need to end costly price controls that stymie groundbreaking medicines and cures and increase costs on American households.”Â
Signatories include David Williams of the Taxpayers Protection Alliance, Pete Sepp of the National Taxpayers Union, and Grover Norquist of Americans for Tax Reform, along with more than a dozen other policy and economic organizations.
The coalition emphasized that addressing pharmaceutical pricing disparities could strengthen trade relations while ensuring continued investment in new treatments and cures.
